Binding specificity of P[8] VP8* proteins of rotavirus vaccine strains with histo-blood group antigens

Virology

Volumn 495, Issue , 2016, Pages 129-135

  Sun, Xiaoman ^a,b   Guo, Nijun ^c   Li, Dandi ^a,b   Jin, Miao ^a,b   Zhou, Yongkang ^a,b   Xie, Guangcheng ^a,b   Pang, Lili ^a,b   Zhang, Qing ^a,b   Cao, Youde ^c   Duan, Zhao Jun ^a,b  

^a BEIJING HOSPITAL   (China)

^b National Institute for Viral Disease Control and Prevention   (China)

^c HUNAN NORMAL UNIVERSITY   (China)

Author keywords

Crystal structure; Histo blood group antigens; Rotarix; RotaTeq; VP8*

Indexed keywords

BLOOD GROUP ANTIGEN; OLIGOSACCHARIDE; UNCLASSIFIED DRUG; VIRUS PROTEIN; VP8 PROTEIN; NS35 PROTEIN, ROTAVIRUS; PROTEIN BINDING; RECOMBINANT PROTEIN; RNA BINDING PROTEIN; ROTAVIRUS VACCINE; VIRAL PROTEIN;

ARTICLE; BINDING AFFINITY; BLOOD GROUP ABO SYSTEM; CONTROLLED STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; ROTAVIRUS; SALIVA; STRUCTURE ANALYSIS; AMINO ACID SEQUENCE; CHEMISTRY; HUMAN; IMMUNOLOGY; METABOLISM; MOLECULAR MODEL; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; BLOOD GROUP ANTIGENS; HUMANS; MODELS, MOLECULAR; OLIGOSACCHARIDES; PROTEIN BINDING; PROTEIN CONFORMATION; RECOMBINANT PROTEINS; RNA-BINDING PROTEINS; ROTAVIRUS; ROTAVIRUS VACCINES; SALIVA; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84969256100     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2016.05.010     Document Type: Article

References (34)

1. Adams P.D., Afonine P.V., Bunkoczi G., Chen V.B., Davis I.W., Echols N., Headd J.J., Hung L.W., Kapral G.J., Grosse-Kunstleve R.W., McCoy A.J., Moriarty N.W., Oeffner R., Read R.J., Richardson D.C., Richardson J.S., Terwilliger T.C., Zwart P.H. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 2010, 66:213-221.
2. Anh D.D., Carlos C.C., Thiem D.V., Hutagalung Y., Gatchalian S., Bock H.L., Smolenov I., Suryakiran P.V., Han H.H. Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 (Rotari)x) (oral suspension (liquid formulatio)n) (when co-administered with expanded program on immunization (EPI) vaccines in Vietnam and the Philippines in) 2006-2007. Vaccine 2011, 29:2029-2036.
3. Ayouni S., Sdiri-Loulizi K., de Rougemont A., Estienney M., Ambert-Balay K., Aho S., Hamami S., Aouni M., Neji-Guediche M., Pothier P., Belliot G. Rotavirus P[8] infections in persons with secretor and nonsecretor phenotypes, Tunisia. Emerg. Infect. Dis. 2015, 21:2055-2058.
4. Bohm R., Fleming F.E., Maggioni A., Dang V.T., Holloway G., Coulson B.S., von Itzstein M., Haselhorst T. Revisiting the role of histo-blood group antigens in rotavirus host-cell invasion. Nat. Commun. 2015, 6:5907.
5. Cortes J.E., Curns A.T., Tate J.E., Cortese M.M., Patel M.M., Zhou F., Parashar U.D. Rotavirus vaccine and health care utilization for diarrhea in U.S. children. N. Engl. J. Med. 2011, 365:1108-1117.
6. Dennehy P.H. Effects of vaccine on rotavirus disease in the pediatric population. Curr. Opin. Pediatr. 2012, 24:76-84.
7. Dormitzer P.R., Sun Z.Y., Wagner G., Harrison S.C. The rhesus rotavirus VP4 sialic acid binding domain has a galectin fold with a novel carbohydrate binding site. EMBO J. 2002, 21:885-897.
8. Doro R., Farkas S.L., Martella V., Banyai K. Zoonotic transmission of rotavirus: surveillance and control. Expert Rev. Anti-Infect. Ther. 2015, 13:1337-1350.
9. Duan Z.J., Liu N., Yang S.H., Zhang J., Sun L.W., Tang J.Y., Jin Y., Du Z.Q., Xu J., Wu Q.B., Tong Z.L., Gong S.T., Qian Y., Ma J.M., Liao X.C., Widdowson M.A., Jiang B., Fang Z.Y. Hospital-based surveillance of rotavirus diarrhea in the People's Republic of China, august 2003-july 2007. J. Infect. Dis. 2009, 200(Suppl. 1):S167-S173.
10. Emsley P., Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 2004, 60:2126-2132.
11. Gentsch J.R., Laird A.R., Bielfelt B., Griffin D.D., Banyai K., Ramachandran M., Jain V., Cunliffe N.A., Nakagomi O., Kirkwood C.D., Fischer T.K., Parashar U.D., Bresee J.S., Jiang B., Glass R.I. Serotype diversity and reassortment between human and animal rotavirus strains: implications for rotavirus vaccine programs. J. Infect. Dis. 2005, 192(Suppl. 1):S146-S159.
12. Gunaydin G., Nordgren J., Sharma S., Hammarstrom L. Association of elevated rotavirus-specific antibody titers with HBGA secretor status in Swedish individuals: the FUT2 gene as a putative susceptibility determinant for infection. Virus Res. 2016, 211:64-68.
13. Haselhorst T., Fleming F.E., Dyason J.C., Hartnell R.D., Yu X., Holloway G., Santegoets K., Kiefel M.J., Blanchard H., Coulson B.S., von Itzstein M. Sialic acid dependence in rotavirus host cell invasion. Nat. Chem. Biol. 2009, 5:91-93.
14. Hu L., Crawford S.E., Czako R., Cortes-Penfield N.W., Smith D.F., Le Pendu J., Estes M.K., Prasad B.V. Cell attachment protein VP8* of a human rotavirus specifically interacts with A-type histo-blood group antigen. Nature 2012, 485:256-259.
15. Hu L., Ramani S., Czako R., Sankaran B., Yu Y., Smith D.F., Cummings R.D., Estes M.K., Venkataram Prasad B.V. Structural basis of glycan specificity in neonate-specific bovine-human reassortant rotavirus. Nat. Commun. 2015, 6:8346.
16. Huang P., Xia M., Tan M., Zhong W., Wei C., Wang L., Morrow A., Jiang X. Spike protein VP8* of human rotavirus recognizes histo-blood group antigens in a type-specific manner. J. Virol. 2012, 86:4833-4843.
17. Imbert-Marcille B.M., Barbe L., Dupe M., Le Moullac-Vaidye B., Besse B., Peltier C., Ruvoen-Clouet N., Le Pendu J. A FUT2 gene common polymorphism determines resistance to rotavirus A of the P[8] genotype. J. Infect. Dis. 2014, 209:1227-1230.
18. Kuhlenschmidt T.B., Hanafin W.P., Gelberg H.B., Kuhlenschmidt M.S. Sialic acid dependence and independence of group A rotaviruses. Adv. Exp. Med. Biol. 1999, 473:309-317.
19. Ma X., Li D.D., Sun X.M., Guo Y.Q., Xiang J.Y., Wang W.H., Zhang L.X., Gu Q.J., Duan Z.J. Binding patterns of rotavirus genotypes P[4], P[6], and P[8] in China with histo-blood group antigens. PloS One 2015, 10:e0134584.
20. Matthijnssens J., Ciarlet M., McDonald S.M., Attoui H., Banyai K., Brister J.R., Buesa J., Esona M.D., Estes M.K., Gentsch J.R., Iturriza-Gomara M., Johne R., Kirkwood C.D., Martella V., Mertens P.P., Nakagomi O., Parreno V., Rahman M., Ruggeri F.M., Saif L.J., Santos N., Steyer A., Taniguchi K., Patton J.T., Desselberger U., Van Ranst M. Uniformity of rotavirus strain nomenclature proposed by the Rotavirus Classification Working Group (RCWG). Arch. Virol. 2011, 156:1397-1413.
21. Matthijnssens J., Joelsson D.B., Warakomski D.J., Zhou T., Mathis P.K., van Maanen M.H., Ranheim T.S., Ciarlet M. Molecular and biological characterization of the 5 human-bovine rotavirus (WC3)-based reassortant strains of the pentavalent rotavirus vaccine, RotaTeq. Virology 2010, 403:111-127.
22. Murshudov G.N., Vagin A.A., Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 1997, 53:240-255.
23. Nordgren J., Sharma S., Bucardo F., Nasir W., Gunaydin G., Ouermi D., Nitiema L.W., Becker-Dreps S., Simpore J., Hammarstrom L., Larson G., Svensson L. Both Lewis and secretor status mediate susceptibility to rotavirus infections in a rotavirus genotype-dependent manner. Clin. Infect. Dis. 2014, 59:1567-1573.
24. Otwinowski Z., Minor W. Processing of X-ray diffraction data collected in oscillation mode. Method Enzymol. 1997, 276:307-326.
25. Padilla-Noriega L., Dunn S.J., Lopez S., Greenberg H.B., Arias C.F. Identification of two independent neutralization domains on the VP4 trypsin cleavage products VP5* and VP8* of human rotavirus ST3. Virology 1995, 206:148-154.
26. Payne D.C., Currier R.L., Staat M.A., Sahni L.C., Selvarangan R., Halasa N.B., Englund J.A., Weinberg G.A., Boom J.A., Szilagyi P.G., Klein E.J., Chappell J., Harrison C.J., Davidson B.S., Mijatovic-Rustempasic S., Moffatt M.D., McNeal M., Wikswo M., Bowen M.D., Morrow A.L., Parashar U.D. Epidemiologic association between FUT2 secretor status and severe rotavirus gastroenteritis in children in the United States. JAMA Pediatr. 2015, 169:1040-1045.
27. Pesavento J.B., Crawford S.E., Estes M.K., Prasad B.V. Rotavirus proteins: structure and assembly. Curr. Top. Microbiol. Immunol. 2006, 309:189-219.
28. Ravn V., Dabelsteen E. Tissue distribution of histo-blood group antigens. APMIS 2000, 108:1-28.
29. Read R.J. Pushing the boundaries of molecular replacement with maximum likelihood. Acta Crystallogr. D Biol. Crystallogr. 2001, 57:1373-1382.
30. Settembre E.C., Chen J.Z., Dormitzer P.R., Grigorieff N., Harrison S.C. Atomic model of an infectious rotavirus particle. EMBO J. 2011, 30:408-416.
31. Tan M., Jin M., Xie H., Duan Z., Jiang X., Fang Z. Outbreak studies of a GII-3 and a GII-4 norovirus revealed an association between HBGA phenotypes and viral infection. J. Med. Virol. 2008, 80:1296-1301.
32. Tate, J.E., Burton, A.H., Boschi-Pinto, C., Steele, A.D., Duque, J., Parashar, U.D., Network, W.H.-c.G.R.S., 2012. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect. Dis. 12, 136-141.
33. Van Trang N., Vu H.T., Le N.T., Huang P., Jiang X., Anh D.D. Association between norovirus and rotavirus infection and histo-blood group antigen types in Vietnamese children. J. Clin. Microbiol. 2014, 52:1366-1374.
34. Ward R.L., Bernstein D.I. Rotarix: a rotavirus vaccine for the world. Clin. Infect. Dis. 2009, 48:222-228.